Clinical trials: Kidney Function
End Stage Kidney Disease
The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients
The purpose of this study is to explore the impact of an intradialytic exercise program on functional capacity, aerobic capacity, strength, quality of life, depression, hospitalizations and intradialytic episodes of hypotension.
- Trial name
- NCT01877863
- Testing
- exercise
- Where
- Canada
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Sugammadex, Neostigmine
Neostigmine Versus Sugammadex on Renal Functions
The study will assess the acute effects of sugammadex or neostigmine on renal function as determined with more specific and sensitive tests in laparoscopic cholecystectomy
- Trial name
- NCT06081738
- Testing
- Neostigmine, Sugammadex
- Where
- Egypt
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Menoufia University
Renal Impairment
Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function
This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.
- Trial name
- NCT01372826
- Testing
- NKTR118 Group1, NKTR118 Group 2, NKTR118 Group3
- Where
- 3 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Renal Insufficiency, Kidney Diseases
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
This is a multi-center, open-label, parallel-group study to evaluate oral doses of INCB054707 in participants with varying levels of renal function or impairment.
- Trial name
- NCT05624723
- Testing
- INCB054707
- Where
- 2 sites in United States, Germany
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Kidney Functional
GLP-1: Acute Effects on Kidney Function in Healthy Men
The purpose of this study is to investigate how Glucagon-Like Peptide 1 (GLP-1) affects kidney function in healthy young men. The hypothesis is that GLP-1 induces a positive effect on kidney hemodynamics.
- Trial name
- NCT01333163
- Testing
- Human GLP-1 (7-36) amide, Isotone NaCl
- Where
- Denmark
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Jeppe Skov
Kidney Transplantation, Urinary Calculi
Evaluation of Kidney Function by Multi-modal Magnetic Resonance Imaging and Spectroscopy
Multimodal functional magnetic resonance (MR) methods, including MR diffusion, Blood-Oxygenation Level Dependent (BOLD) imaging and MR spectroscopy may provide complementary information about the functional status of a kidney.
- Trial name
- NCT00575432
- Testing
- diffusion MRI, BOLD MRI, Clinical Outcome
- Where
- Switzerland
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Renal Impairment
Pharmacokinetics in Subjects With Renal Impairment
This is an open-label, non-randomized, parallel-group, mono-center, single intravenous dose, Phase I trial to investigate the Pharmacokinetic (PK) and safety of cilengitide in subjects with different grades of renal impairment as…
- Trial name
- NCT01504165
- Testing
- cilengitide 2000mg, cilengitide 1000mg, cilengitide > 1000mg and up to 2000mg
- Where
- 2 sites in Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Merck KGaA, Darmstadt, Germany
Renal Impairment
Assessment of Renal Function by Multiparametric MRI
Metabolic syndrome is a collection of conditions that affect at least three of the following five criteria: abdominal obesity, high blood pressure, high fasting glucose levels, high triglyceride levels, and low levels of…
- Trial name
- NCT06407375
- Testing
- mpMRI
- Where
- Switzerland
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Migraine
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
This is a multi-center, open-label, non-randomized, parallel-group, adaptive, single dose study. This study will enroll up to 32 participants using an adaptive design that can include up to 3 groups of 8 participants with…
- Trial name
- NCT03009162
- Testing
- Lasmiditan
- Where
- 2 sites in Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Pharmacokinetic
A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol
The objective of this study was to evaluate the pharmacokinetics (PK), safety and tolerability profile of cebranopadol (GRT6005) in patients with varying degree of renal impairment and participants with normal renal function…
- Trial name
- NCT03882762
- Testing
- Cebranopadol 200 μg tablet
- Where
- 2 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Tris Pharma, Inc.
Renal Insufficiency, Chronic, Cardiac Catheterization
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
This study aim to investigate the protected effects of short-term use of dapagliflozin (administered within 3 days after procedure) in CKD patients after coronary angiography or percutaneous coronary intervention, as well as…
- Conditions
- Renal Insufficiency, Chronic, Cardiac Catheterization, Percutaneous Coronary Intervention
- Trial name
- NCT05225077
- Testing
- Dapagliflozin 10 MG [Farxiga]
- Where
- South Korea
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Dong-A University
Healthy Volunteer, Renal Impairment
Study of AT-527 in Subjects With Normal and Impaired Renal Function
Study of AT-527 in Subjects with Normal and Impaired Renal Function
- Trial name
- NCT05618314
- Testing
- AT-527, AT-527 and Probenecid
- Where
- Canada
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Kidney Impairment
A Study of RAY1225 in Participants With Impaired Kidney Function
The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
- Trial name
- NCT06613763
- Testing
- RAY1225
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Guangdong Raynovent Biotech Co., Ltd
Dyslipidemia
Pharmacokinetics of Anacetrapib (MK0859) in Subjects With Impaired Renal Function (MK-0859-038)
This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib in subjects with impaired renal function and healthy matched control subjects.
- Trial name
- NCT01122667
- Testing
- anacetrapib
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
IGA Glomerulonephritis
Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy
OBJECTIVES: I. Determine the most sensitive outcome measures (functional or morphological) of a progressive renal injury in patients with IgA nephropathy. II.
- Trial name
- NCT00006137
- Testing
- enalapril
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Center for Research Resources (NCRR)
Proton Pump Inhibitor Allergy
Effect of Proton Pump Inhibitor of Daily Use for One Month on Kidney Function Test
The aim of this study to: evaluate the association between prolonged use of PPI and adverse renal outcomes on patients with normal renal function and others with abnormal renal function
- Trial name
- NCT04022837
- Testing
- Pantoprazole 40mg
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assiut University
Pharmacokinetics and Pharmacodynamics
Vancomycin Dose Optimization in Obesity
The goal of this clinical trial is to learn how to optimize vancomycin dosing in obese adults based on weight and kidney function. It will also assess the safety of different vancomycin dosing strategies.
- Trial name
- NCT06601257
- Testing
- Vancomycin (IV)
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Myelofibrosis
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Renal Impairment Subjects
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with renal impairment after a single dose, and to evaluate the urinary…
- Trial name
- NCT06598956
- Testing
- TQ05105
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Alzheimer's Disease, Huntington's Disease
A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function
This study is to compare the pharmacokinetics of Dimebon in subjects with severe renal impairment to subjects with normal renal function after oral administration of a single oral 20-mg dose of Dimebon.
- Trial name
- NCT00824590
- Testing
- Dimebon
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Blood Pressure, Hydration
Potassium, Hydration, Cardiovascular, and Kidney Study (PHACKs)
Compared with White Adults, Non-Hispanic Black Adults are at an elevated risk of developing cardiovascular disease (CVD) and end stage chronic-kidney disease (CKD), two of the leading causes of death in the United States.
- Conditions
- Blood Pressure, Hydration, Vascular Disease Risk
- Trial name
- PHACKs (NCT06062017)
- Testing
- Water and Potassium supplementation
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Auburn University